204 related articles for article (PubMed ID: 20734110)
1. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
Kang BW; Kim JG; Chae YS; Lee YJ; Lee SJ; Moon JH; Sohn SK; Jung MK; Jeon SW; Jang YJ; Seo J; Lee YH; Kwon O; Chung HY; Yu W
Invest New Drugs; 2012 Aug; 30(4):1671-5. PubMed ID: 21845514
[TBL] [Abstract][Full Text] [Related]
3. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
[TBL] [Abstract][Full Text] [Related]
4. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY
Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
7. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G;
Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
[TBL] [Abstract][Full Text] [Related]
9. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
Li YH; Qiu MZ; Xu JM; Sun GP; Lu HS; Liu YP; Zhong MZ; Zhang HL; Yu SY; Li W; Hu XH; Wang JJ; Cheng Y; Zhou JT; Guo ZQ; Guan ZG; Xu RH
Oncotarget; 2015 Oct; 6(33):35107-15. PubMed ID: 26439700
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
Kang BW; Jeong JY; Chae YS; Lee SJ; Lee YJ; Choi JY; Lee IK; Jeon SW; Bae HI; Lee DK; Kwon OK; Chung HY; Yu W; Kim JG
Cancer Chemother Pharmacol; 2012 Nov; 70(5):735-41. PubMed ID: 22955258
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
Yoon S; Yoo C; Ryu MH; Kang MJ; Ryoo BY; Park SR; Yook JH; Oh ST; Yoo MW; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):182-189. PubMed ID: 26661592
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
14. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106).
Kurimoto K; Ishigure K; Mochizuki Y; Ishiyama A; Matsui T; Ito S; Nakayama H; Tanaka N; Kobayashi D; Sakamoto J; Nakao A; Kodera Y
Gastric Cancer; 2015 Apr; 18(2):354-9. PubMed ID: 24838732
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
Atiq OT; Kelsen DP; Shiu MH; Saltz L; Tong W; Niedzwiecki D; Trochanowski B; Lin S; Toomasi F; Brennan M
J Clin Oncol; 1993 Mar; 11(3):425-33. PubMed ID: 8445416
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
